Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Wakamoto to Set Up JV for Generics with Taiwan Drugmaker
May 2, 2011
- HSC Approves Draft Report on Measures against Rheumatism
May 2, 2011
- Moratorium on Copayment by Quake Victims to Be Extended: Korosho
May 2, 2011
- Kyowa Kirin Completes Legal Procedures for Acquisition of ProStrakan
May 2, 2011
- Chugai's Pegasys Granted Priority Review Status for CHB
May 2, 2011
- Outgoing KEIZAI DOYUKAI Chairman Expresses Hope for His Successor from Regulation-bound Industry
May 2, 2011
- Kaken to Achieve Its Operating Profits Goal: Mizuho Securities
May 2, 2011
- Gov't Designates Eribulin as Ad-restricted Drug
May 2, 2011
- Sugi HD: Sales from Dispensing Services Up 16% to ¥24.8 Bil.
May 2, 2011
- CoreMed Offers New Service to Increase Efficiency of eCTD Filing
May 2, 2011
- Korosho to Consider Allowing Home Delivery of OTC Drugs by Pharmacists
May 2, 2011
- FPMAJ Finalizes Voluntary Plan for Energy-saving this Summer
May 2, 2011
- Acronet, ICON to Collaborate in CRO Business
May 2, 2011
- OTC Ketotifen to be Reclassified as Class 2
May 2, 2011
- FPMAJ Proposes Rotating Production for Some Makers this Summer
May 2, 2011
- “Generally Favorable”Outlook for Dispensing Pharmacies in FY2011: Analyst
May 2, 2011
- What Is on the Mind of Japan's Pharmaceutical Executives?
May 2, 2011
- Quake-hit Plant to Return to Full Operation by Sept.: Chugai
May 2, 2011
- 33 Drugs Approved Including LIXIANA
May 2, 2011
- Bayer Starts Multinational PIII Trial for VEGF Trap-Eye in DME
May 2, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…